Clinical evaluation is at the heart of getting and keeping medical devices on the market in both the EU and US. Under the EU MDR, that means a robust, defendable Clinical Evaluation Report (CER). In the US, it means a clear, integrated clinical evidence story within your 510(k), De Novo, or PMA. Weak clinical evaluation is one of the most common reasons for delays, non‑conformities, and extra study requests.
Sharp Regulatory Consulting helps device manufacturers build clinical evidence packages that stand up to scrutiny on both sides of the Atlantic—whether you’re preparing an MDR CER, a PMA, or a global strategy that must satisfy Notified Bodies and FDA simultaneously.
The first take home here is that clinical investigations and clinical evaluations for medical devices are not the same thing. An investigation is a single study, an evaluation is a review of the totality of the clinical information available for the device which may include investigations, literature and in use data.
Both in the EU and US clinical evaluation is required — but the expectations, terminology, and documentation differ.
EU: Clinical Evaluation Report (CER) under MDR
In the EU, a Clinical Evaluation Report (CER) is a formal document required under the Medical Devices Regulation (MDR 2017/745). It:
- Demonstrates that the device achieves its intended clinical benefits
- Shows that risks are acceptable in relation to those benefits
- Synthesizes all relevant clinical data (own studies, literature, PMS/PMCF, registries, etc.)
The CER is part of the technical documentation reviewed by the Notified Body (for most devices).
The report is typically aligned with MEDDEV 2.7/1 rev. 4 and MDR and contains:
- Device description and intended purpose
- Clinical background and state of the art
- Clinical development strategy and rationale
- Identification and appraisal of clinical data
- Analysis of clinical data against GSPRs (safety, performance)
- Conclusions on benefit–risk, residual risks, uncertainties
- Link to risk management, IFU, and PMCF plan
When it’s required: Before CE marking for all classes (I–III, including IVDs under IVDR with analogous reports)
Updated regularly: At least annually for high‑risk devices. At defined intervals for lower‑risk devices, or when significant new data emerge
US: Closest equivalents
The US does not use the term “CER,” but similar expectations are embedded in:
- 510(k) submissions: Substantial equivalence supported by clinical or non‑clinical data as needed
- De Novo requests and PMAs: Full clinical evidence packages with:
- Clinical study reports
- Integrated summaries of safety and effectiveness
- Risk–benefit analyses
While the US doesn’t require a stand‑alone CER document, FDA reviewers expect a coherent, integrated clinical evidence narrative and clear linkage to indications, labelling, and risk management.
Key differences: EU vs US
EU: CER is a defined, mandatory document with prescriptive guidance.
US: No specific CER format, but equivalent clinical justification is built into submission modules.
“State of the art” and literature
EU: Strong emphasis on systematic literature review and comparison with clinical practice and alternatives.
US: Literature is important but often plays a more supportive role; weight is on pivotal trial data for higher‑risk devices.
Equivalence
EU: Use of clinical equivalence to other devices is possible but heavily scrutinized under MDR.
US: “Substantial equivalence” is a legal construct in 510(k) but must be supported by technological comparison and, where needed, clinical data.
Practical tips for strong clinical evaluations
- Start early, not at submission time
- Build clinical evaluation planning into your overall development plan.
- Define early: what evidence you need, from whom, and by when.
- Be systematic with literature
- Use transparent search strategies (databases, terms, dates, inclusion/exclusion).
- Document how you selected, appraised, and weighted each source.
- Align CER with other documentation
Claims in CER must be consistent with:
- IFU / labelling
- Risk management file (ISO 14971)
- Clinical investigation plans and reports
- PMS / PMCF plans and reports
Inconsistencies are a common trigger for questions or non‑conformities.
Justify equivalence carefully (EU)
- Demonstrate clinical, technical, and biological equivalence if relying on another device’s data.
- Ensure legally valid access to equivalent device data (often problematic under MDR).
- If equivalence is weak, plan for your own clinical investigation instead.
- Use real‑world data wisely
- Complaints, registries, user feedback, and observational data can be powerful, especially for long‑term safety and performance, but they must be:
- Well‑documented
- Critically appraised for bias and data quality
- Keep the CER “live”
CER is not one‑and‑done. Update when:
- New significant safety/efficacy data arise
- Indications or design change
- PMS/PMCF reveal new findings
Common pitfalls to avoid
- Superficial or outdated literature reviews
- Narrow searches, no clear methodology, or ignoring negative data.
- Unsubstantiated clinical claims
- Marketing language not supported by data (e.g., “best in class,” “superior”).
- Overstating effectiveness in subgroups without robust evidence.
- Ignoring or minimizing unfavourable data
- Not discussing complications, failures, or conflicting studies; regulators expect balanced analysis.
- Weak linkage to risk management
- Risks identified in clinical data not reflected in risk file, labelling, or IFU warnings
- Lack of US–EU alignment in global programs
- Designing US clinical studies that do not collect endpoints or populations needed to satisfy MDR expectations.
- Not planning for EU “state of the art” and equivalence scrutiny when trials are US‑
In summary, both EU and US expect rigorous, transparent clinical justification for device safety and performance. The EU requires a structured Clinical Evaluation Report, while the US embeds similar expectations into its submission format. Strong planning, systematic evidence appraisal, and alignment across documents are essential to avoid delays, non‑conformities, or additional study demands.
If you’re planning an MDR certification, facing a CER update, or preparing clinical components of a US submission, Sharp Regulatory Consulting can help you turn fragmented data into a coherent, defensible clinical evidence package—and reduce the risk of costly surprises late in the process.